ZGNX - Zogenix +5.7% furthers studies on Dravet syndrome drug

Zogenix (ZGNX) adds new analyses for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome. Dravet syndrome is a rare, highly refractory form of infant- and childhood-onset epilepsy marked by frequent and often prolonged seizures that are difficult to control with existing medications, significant cognitive and motor impairments, and a higher risk of sudden death.“In addition to the significant convulsive seizure reductions seen in all three multi-national Phase 3 studies of FINTEPLA in Dravet syndrome, we are proud to collaborate with expert clinician investigators to show the durability of the clinically meaningful seizure reduction that FINTEPLA provided for patients treated for up to two years,” said Bradley S. Galer, M.D., Executive VP and Chief Medical Officer at Zogenix. New post-hoc data analysis from our studies demonstrated that for every two to three patients treated with FINTEPLA, one patient achieved ?75% (profound) convulsive seizure reduction compared with placebo.Shares +5.7% after hours

For further details see:

Zogenix +5.7%, furthers studies on Dravet syndrome drug